Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. News about CMPX often centers on its antibody pipeline, clinical trial progress, financing activities, and corporate developments, reflecting its focus on angiogenesis, immune modulation, and tumor growth.
Investors and observers following Compass Therapeutics news can expect regular updates on key product candidates such as tovecimig, CTX-8371, CTX-10726, and CTX-471. The company issues press releases on milestones in the COMPANION-002 Phase 2/3 study of tovecimig in advanced biliary tract cancer, monotherapy data in metastatic colorectal cancer, and cohort expansions or new responses in the Phase 1 study of CTX-8371 in indications like non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma. Preclinical data releases for CTX-10726, including presentations at scientific meetings, also feature prominently.
Compass Therapeutics news coverage additionally includes quarterly financial results, cash and marketable securities updates, and descriptions of anticipated cash runway, as disclosed in earnings press releases and related Form 8-K filings. The company also announces public offerings of common stock and pre-funded warrants, with details on intended use of proceeds for research, clinical development, and preparations for potential commercialization.
Another recurring theme in CMPX news is participation in healthcare and biopharma investor conferences, where Compass presents its pipeline and corporate strategy. Press releases list appearances at events hosted by firms such as J.P. Morgan, Piper Sandler, Evercore, Guggenheim, Stifel, Cantor, and others. Leadership appointments, including additions to the senior management team, are also communicated through Globe Newswire releases.
This news page aggregates these company-issued updates and related coverage, offering a centralized view of clinical, scientific, financial, and corporate developments for Compass Therapeutics and its CMPX stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
